Synopsis: After generating Rs. 148 crore in revenue during FY26, two of TTK Healthcare’s established consumer brands are set to change hands in a Rs. 256 crore deal with Wipro Enterprises Private Limited. With the brands contributing 17 percent of the company’s total turnover, the transaction marks one of the company’s most significant strategic moves in recent years. Here’s what the deal means and why investors are watching it closely.
Brand acquisitions have become an increasingly common strategy in India’s FMCG sector as companies look to strengthen their product portfolios through established brands instead of building new ones from scratch. Continuing this trend, TTK Healthcare Limited has entered into a definitive agreement to divest its well-known EVA and Good Home brands to Wipro Enterprises Private Limited.
Shares of TTK Healthcare Limited were trading at Rs 1,010.35, up by 0.43 percent from the previous close of Rs 1,006. The stock opened at Rs 1,008.9 and reached an intraday high of Rs 1,062.4, with a day’s low of Rs 990. The company currently has a market capitalisation of Rs 1,429 crore.
TTK Healthcare Approves Sale of Two Consumer Brands
TTK Healthcare Limited has announced that its Board of Directors, based on the recommendation of the Audit Committee, has approved the sale of its well-known consumer brands, ‘EVA’ and ‘Good Home’, to Wipro Enterprises Private Limited.
The company stated that definitive agreements for the transaction were executed on July 23, 2026, with the completion of the transaction subject to the fulfilment of customary conditions precedent.
The proposed transaction represents a strategic portfolio realignment for the company, allowing it to monetise two established brands while entering into a definitive agreement with Wipro Enterprises, one of India’s diversified consumer products companies. The company expects the transaction to be completed on or before September 30, 2026, subject to regulatory and contractual conditions.
Deal Valued at Rs. 256 Crore
Under the terms of the agreement, TTK Healthcare will receive Rs 256 crore plus applicable GST for the sale of the two brands. The company clarified that the transaction is not a related-party transaction, as Wipro Enterprises Private Limited does not belong to the promoter group of TTK Healthcare. Additionally, the company confirmed that the sale is not being undertaken as a slump sale.
The consideration is expected to strengthen the company’s liquidity and could provide additional financial flexibility for future investments, debt reduction, or expansion into its core businesses. However, the company has not disclosed its intended utilisation of the sale proceeds in the exchange filing.
Brands Accounted for 17% of FY26 Revenue
The brands being sold generated approximately Rs. 148 crore in revenue during FY2025-26, representing around 17 percent of TTK Healthcare’s total turnover for the financial year. The transaction, therefore, involves a meaningful portion of the company’s consumer products business and points out the importance of the divestment.
While the sale will result in the company exiting ownership of these two brands, investors will closely monitor how TTK Healthcare redeploys the proceeds and whether the divestment improves profitability and capital allocation over the medium term. Further updates regarding the strategic direction following the sale are expected once the transaction is completed.
The announcement demonstrates TTK Healthcare’s ongoing efforts to reshape its brand portfolio through strategic divestments while enabling Wipro Enterprises to strengthen its presence in India’s fast-moving consumer products segment through the acquisition of established brands.
Financial Highlights
The company reported a steady performance in Q4 FY26 compared with Q3 FY26. Revenue from operations increased 4.3% QoQ to Rs. 218 crore in Q4 FY26 from Rs. 209 crore in Q3 FY26.
Operating performance improved at a faster pace, with operating profit rising 57.1% QoQ to Rs. 11 crore from Rs. 7 crore, while the operating profit margin expanded to 5% from 3%, indicating better cost efficiency during the quarter.
Profitability witnessed a strong sequential recovery. Profit Before Tax (PBT) increased 114.3% QoQ to Rs. 30 crore in Q4 FY26 from Rs. 14 crore in Q3 FY26, while net profit doubled to Rs. 22 crore from Rs. 11 crore. Consequently, EPS surged 106.7% QoQ to Rs. 15.40 in Q4 FY26 from Rs. 7.45 in Q3 FY26, reflecting a significant improvement in shareholder earnings.
The company continues to maintain a robust balance sheet with cash and cash equivalents of Rs. 633 crore, working capital of Rs. 1,012 crore, a current ratio of 5.91, and a debt-to-equity ratio of just 0.02, indicating negligible leverage.
Over the longer term, the business has delivered a 5-year sales CAGR of 12% and a 10-year profit CAGR of 12%, although the 3-year profit CAGR remains negative at -52%, highlighting earnings volatility in recent years.
Insight & Industry Analysis
TTK Healthcare sold EVA and Good Home, which accounted for nearly 17% of its FY26 turnover, as part of its portfolio rationalisation. Selling these consumer brands for Rs. 256 crore could improve the company’s balance sheet and allocate capital to businesses aligned with its long-term strategic priorities.
Instead of building new brands, India’s FMCG and consumer products industry often acquires existing brands to expand its product portfolio and leverage brand recognition. How Wipro and other enterprises are integrating these brands and how TTK Healthcare uses the proceeds to support growth will be closely watched by investors.
TTK Healthcare Limited is a diversified healthcare and consumer products company engaged in pharmaceuticals, medical devices, food products, and personal care products. Through a portfolio of healthcare and consumer brands, the company serves both domestic and international markets while continuing to optimise its business portfolio through strategic initiatives and value-accretive transactions.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
